JOAN E. HERMAN - 19 Nov 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Joan E. Herman
Issuer symbol
IONS
Transactions as of
19 Nov 2025
Net transactions value
-$648,430
Form type
4
Filing time
20 Nov 2025, 17:12:11 UTC
Previous filing
16 Oct 2025
Next filing
16 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HERMAN JOAN E Director 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Joan E. Herman 20 Nov 2025 0001248398

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $480,600 +12,000 +26% $40.05 58,086 19 Nov 2025 Direct
transaction IONS Common Stock Sale $865,590 -12,000 -21% $72.13 46,086 19 Nov 2025 Direct F1
transaction IONS Common Stock Options Exercise $2,044,800 +32,000 +69% $63.90 78,086 19 Nov 2025 Direct
transaction IONS Common Stock Sale $2,308,240 -32,000 -41% $72.13 46,086 19 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,000 -100% $0.000000 0 19 Nov 2025 Common Stock 12,000 $40.05 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -32,000 -100% $0.000000 0 19 Nov 2025 Common Stock 32,000 $63.90 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.985 to $72.33 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.